Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Design and engineering of deimmunized biotherapeutics.

Literature DB >> 27322891

Design and engineering of deimmunized biotherapeutics.

Karl E Griswold¹, Chris Bailey-Kellogg².

Abstract

Therapeutic proteins are powerful next-generation drugs able to effectively treat diverse and devastating diseases, but the development and use of biotherapeutics entails unique challenges and risks. In particular, protein drugs are subject to immune surveillance in the human body, and ensuing antidrug immune responses can cause a wide range of problems including altered pharmacokinetics, loss of efficacy, and even life-threating complications. Here we review recent progress in technologies for engineering deimmunized biotherapeutics, placing particular emphasis on deletion of immunogenic antibody and T cell epitopes via experimentally or computationally guided mutagenesis.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2016 PMID： 27322891 PMCID： PMC5067179 DOI： 10.1016/j.sbi.2016.06.003

Source DB: PubMed Journal: Curr Opin Struct Biol ISSN： 0959-440X Impact factor: 6.809

82 in total

1. Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Authors: P C Spiegel; M Jacquemin; J M Saint-Remy; B L Stoddard; K P Pratt
Journal: Blood Date: 2001-07-01 Impact factor: 22.113

2. A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments.

Authors: Lu He; Alan M Friedman; Chris Bailey-Kellogg
Journal: Proteins Date: 2011-12-16

3. Rationally engineered therapeutic proteins with reduced immunogenicity.

Authors: Shabnam Tangri; Bianca R Mothé; Julie Eisenbraun; John Sidney; Scott Southwood; Kristen Briggs; John Zinckgraf; Pamuk Bilsel; Mark Newman; Robert Chesnut; Cynthia Licalsi; Alessandro Sette
Journal: J Immunol Date: 2005-03-15 Impact factor: 5.422

Review 4. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics.

Authors: Johan J F Verhoef; John F Carpenter; Thomas J Anchordoquy; Huub Schellekens
Journal: Drug Discov Today Date: 2014-09-07 Impact factor: 7.851

5. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.

Authors: Masanori Onda; Satoshi Nagata; David J FitzGerald; Richard Beers; Robert J Fisher; James J Vincent; Byungkook Lee; Michihiro Nakamura; Jaulang Hwang; Robert J Kreitman; Raffit Hassan; Ira Pastan
Journal: J Immunol Date: 2006-12-15 Impact factor: 5.426

6. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Authors: Masanori Onda; Richard Beers; Laiman Xiang; Byungkook Lee; John E Weldon; Robert J Kreitman; Ira Pastan
Journal: Proc Natl Acad Sci U S A Date: 2011-03-21 Impact factor: 12.779

7. Removing T-cell epitopes with computational protein design.

Authors: Chris King; Esteban N Garza; Ronit Mazor; Jonathan L Linehan; Ira Pastan; Marion Pepper; David Baker
Journal: Proc Natl Acad Sci U S A Date: 2014-05-19 Impact factor: 12.779

8. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.

Authors: Robert G E Holgate; Richard Weldon; Timothy D Jones; Matthew P Baker
Journal: PLoS One Date: 2015-09-15 Impact factor: 3.240

Review 9. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Authors: Murli Krishna; Steven G Nadler
Journal: Front Immunol Date: 2016-02-02 Impact factor: 7.561

Review 10. Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource.

Authors: Sinu Paul; Ravi V Kolla; John Sidney; Daniela Weiskopf; Ward Fleri; Yohan Kim; Bjoern Peters; Alessandro Sette
Journal: Clin Dev Immunol Date: 2013-10-08

13 in total

Review 1. Searching for the Pareto frontier in multi-objective protein design.

Authors: Vikas Nanda; Sandeep V Belure; Ofer M Shir
Journal: Biophys Rev Date: 2017-08-10

2. Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.

Authors: Regina S Salvat; Deeptak Verma; Andrew S Parker; Jack R Kirsch; Seth A Brooks; Chris Bailey-Kellogg; Karl E Griswold
Journal: Proc Natl Acad Sci U S A Date: 2017-06-12 Impact factor: 11.205

3. FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors: Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal: Blood Adv Date: 2018-02-27

4. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?

Authors: Lotus Mallbris; Julian Davies; Andrew Glasebrook; Ying Tang; Wolfgang Glaesner; Brian J Nickoloff
Journal: J Clin Aesthet Dermatol Date: 2016-07-01

5. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.

Authors: Wojciech Jankowski; Joseph McGill; H A Daniel Lagassé; Stepan Surov; Gary Bembridge; Campbell Bunce; Edward Cloake; Mark H Fogg; Katarzyna I Jankowska; Abdul Khan; Joseph Marcotrigiano; Mikhail V Ovanesov; Zuben E Sauna
Journal: Blood Adv Date: 2019-09-10

6. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.

Authors: Greta Giordano-Attianese; Pablo Gainza; Elise Gray-Gaillard; Elisabetta Cribioli; Sailan Shui; Seonghoon Kim; Mi-Jeong Kwak; Sabrina Vollers; Angel De Jesus Corria Osorio; Patrick Reichenbach; Jaume Bonet; Byung-Ha Oh; Melita Irving; George Coukos; Bruno E Correia
Journal: Nat Biotechnol Date: 2020-02-03 Impact factor: 54.908